Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 6, 2013, Pages 441-449

  Milenic, Diane E ^a,b   Baidoo, Kwamena E ^a   Shih, Joanna H ^a   Wong, Karen J ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

particle; 212Pb; 213Bi; Carboplatin; Cisplatin; HER2; Radioimmunotherapy; Trastuzumab

Indexed keywords

BISMUTH 213; CARBOPLATIN; CISPLATIN; LEAD 212; TRASTUZUMAB;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMA CELL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; LINEAR ENERGY TRANSFER; MOLECULARLY TARGETED THERAPY; MOUSE; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OTOTOXICITY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; WEIGHT REDUCTION;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BISMUTH; CELL LINE, TUMOR; CHEMORADIOTHERAPY; COLONIC NEOPLASMS; FEMALE; HUMANS; LEAD RADIOISOTOPES; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; ORGANOPLATINUM COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880858990     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1423     Document Type: Article

References (38)

1. Milenic D, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004;10:7834.
2. Milenic DE, Garmestani K, Brady ED, et al. Potentiation of high-let radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res 2007;13:1926.
3. Milenic DE, Garmestani K, Brady ED, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005;20:557.
4. Milenic DE, Garmestani K, Brady ED, et al. Multimodality therapy: Potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res 2008;14:5108.
5. 212Bi-labeled antibody. Cancer Res 1990;50:985s.
6. 213Bi-labeled monoclonal antibody against mutant e-cadherin suggests its usefulness for locoregional α- radioimmunotherapy of diffuse-type gastric cancer. Cancer Res 2001;61:2804.
7. 211At-labelled monoclonal antibody mov18. Anticancer Res 2000;20:459.
8. Horak E, Hartmann F, Garmestani K, et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-dota-ae1. J Nucl Med 1997;38: 1944.
9. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 1995;31A:2335.
10. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417.
11. Toschi L, Finocchiaro G, Bartolini S, et al. Role of gemcitabine in cancer therapy. Future Oncol 2005;1:7.
12. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573.
13. Shikani AH, Richtsmeier WJ, Klein JL, Kopher KA. Radiolabeled antibody therapy for squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1992; 118:521.
14. Tom BH, Rutzky LH, Jakstys MH. Human colonic adenocarcinoma cells. Establishment and description of a new cell line. In Vitro 1976;12:180.
15. Xu F, Yu Y, Le XF, et al. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of her-2 and her-3 expression. Clin Cancer Res 1999; 5:3653.
16. Brechbiel MW, Gansow OA. Synthesis of c-functionalized trans-cyclohexyldiethylene-triamine-pentaacetic acids for labelling of monoclonal antibodies with the bismuth-212 α particle emitter. J Chem Soc Perkin Trans 1 1992;1173.
17. 212Pb. Nucl Med Biol 2000;27:93.
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265.
19. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional dtpa ligand in dtpa-monoclonal antibody conjugates. Bioconjug Chem 1992;3:342.
20. Dadachova E, Chappell LL, Brechbiel MW. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 1999;26:977.
21. 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm 2004;19:135.
22. Xu H, Baidoo K, Gunn AJ, et al. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J Med Chem 2007;50: 4759.
23. Buchsbaum DJ, Rogers BE, Khazaeli MB, et al. Targeting strategies for cancer radiotherapy. Clin Cancer Res 1999;5: 3048s.
24. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. (212) Pbradioimmunotherapy induces g(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther 2012; 11:639.
25. Gregoire V, Van NT, Stephens LC, et al. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 1994;54:6201.
26. Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Ann Intern Med 1984;100:704.
27. Aratani Y, Yoshiga K, Mizuuchi H, et al. Antitumor effect of carboplatin combined with radiation on tumors in mice. Anticancer Res 1997;17:2535.
28. Hartley C, Elliott S, Begley CG, et al. Kinetics of haematopoietic recovery after dose-intensive chemo/radiotherapy in mice: Optimized erythroid support with darbepoetin alpha. Br J Haematol 2003;122:623.
29. Farrell NP. Preclinical perspectives on the use of platinum compounds in cancer chemotherapy. Semin Oncol 2004;31:1.
30. Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265.
31. Blumenthal RD, Sharkey RM, Natale AM, et al. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 1994;54:142.
32. Kievit E, Pinedo HM, Schluper HM, Boven E. Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323/a3 in experimental human ovarian cancer. Int J Radiat Oncol Biol Phys 1997;38:419.
33. Blumenthal RD, Leone E, Goldenberg DM. Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy. Anticancer Res 2003;23:4613.
34. Blumenthal RD, Leone E, Goldenberg DM, et al. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression. Int J Cancer 2004;108:293.
35. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309.
36. Milenic DE, Wong KJ, Baidoo KE, et al. Targeting HER2: A report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2010;2:550.
37. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. Sensitization of tumor to (212)Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with rad51. Int J Radiat Oncol Biol Phys 2013;267:173.
38. Levy AD, Shaw JC, Sobin LH. Secondary tumors and tumorlike lesions of the peritoneal cavity: Imaging features with pathologic correlation. Radiographics 2009;29: 347.